Establishing the Burden and Potential Preventive Impact of RSV Vaccine for All Young Children
Focus: The Respiratory Syncytial Virus (RSV) Vaccines Working Group has been convened to review and advise on the best strategies for avoiding the unnecessary hospitalisation of under 5s by the use of RSV vaccinations across Europe. Looking at the healthcare burden of hospitalisation in the first instance. This new area has the potential to significantly cut the number of hospitalisations per year (estimated to be 30,000 in the UK alone), but we must decide on the most successful strategy to establish RSV vaccinations in vaccine schedules over the coming years.
If you wish to participate nominate yourself or your organisation